-
公开(公告)号：US20190225648A1
公开(公告)日：2019-07-25
申请号：US16359763
申请日：2019-03-20
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Friedrich Scheiflinger , Michael Dockal
IPC: C07K7/06 , C07K7/08 , C07K1/04 , C07K14/755
Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO:1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
-
公开(公告)号：US10036002B2
公开(公告)日：2018-07-31
申请号：US14824870
申请日：2015-08-12
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Meinhard Hasslacher , Thomas Gatternig , Christian Fiedler , Ernst Böhm , Michael Dockal , Franziska Horling
CPC classification number: C12N9/6432 , C12Y304/21006
Abstract: Methods and systems for activating Factor X are disclosed.
-
公开(公告)号：US20170360823A1
公开(公告)日：2017-12-21
申请号：US15696111
申请日：2017-09-05
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Michael Dockal , Fritz Scheiflinger , Sabine Knappe , Susanne Till , Ton Hai , Paul Sanders , Prasad Dande , Cong Jiang
IPC: A61K31/737 , C07H5/10 , A61K45/06 , C08B37/16 , A61K31/715
CPC classification number: A61K31/737 , A61K31/715 , A61K45/06 , C07H5/10 , C08B37/0012 , A61K2300/00
Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.
-
公开(公告)号：US20170035835A1
公开(公告)日：2017-02-09
申请号：US15242002
申请日：2016-08-19
Applicant: BAXALTA INCORPORATED , BAXALTA GMBH
Inventor： Michael Dockal , Thomas Polakowski , Frank Osterkamp , Rudolf Hartmann , Matthias Paschke , Bettina Hartlieb , Friedrich Scheiflinger
CPC classification number: A61K38/10 , A61K38/00 , A61K47/60 , C07K7/08 , C07K14/745
Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
Abstract translation: 本发明提供肽，包括结合并任选地抑制蛋白S的肽及其组合物。 肽可以用于例如抑制蛋白S活性，增强受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化蛋白S，并鉴定蛋白S结合化合物。
-
公开(公告)号：US10822376B2
公开(公告)日：2020-11-03
申请号：US16359763
申请日：2019-03-20
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Friedrich Scheiflinger , Michael Dockal
IPC: C07K7/06 , C07K14/755 , C07K7/08 , C07K1/04 , A61K38/00
Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO:1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
-
Patent Agency Ranking
公开(公告)号：US10800816B2
公开(公告)日：2020-10-13
申请号：US15815347
申请日：2017-11-16
Applicant: Baxalta GmbH , Baxalta Incorporated
Inventor： Michael Dockal , Rudolf Hartmann , Friedrich Scheiflinger , Frank Osterkamp , Thomas Polakowski , Ulrich Reineke
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
-
公开(公告)号：US10124033B2
公开(公告)日：2018-11-13
申请号：US15242002
申请日：2016-08-19
Applicant: BAXALTA INCORPORATED , BAXALTA GMBH
Inventor： Michael Dockal , Thomas Polakowski , Frank Osterkamp , Rudolf Hartmann , Matthias Paschke , Bettina Hartlieb , Friedrich Scheiflinger
IPC: A61K38/10 , C07K7/08 , A61K47/60 , A61K38/00 , C07K14/745
Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
-
公开(公告)号：US09777051B2
公开(公告)日：2017-10-03
申请号：US13827160
申请日：2013-03-14
Applicant: BAXALTA GMBH , BAXALTA INCORPORATED
Inventor： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
CPC classification number: C07K14/4703 , A61K38/00 , A61K47/551 , A61K47/557 , A61K47/60 , C07K7/08 , C07K14/001 , Y02A50/463
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
-
公开(公告)号：US20160060295A1
公开(公告)日：2016-03-03
申请号：US14941163
申请日：2015-11-13
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Friedrich Scheiflinger , Michael Dockal
Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
Abstract translation: 一种肽或肽衍生物，其包含：（i）WDLYFEIVW（SEQ ID NO：1）; 或（ii）在WDLYFEIVW（SEQ ID NO：1）中包含一个，两个，三个或四个L-氨基酸取代的变体氨基酸序列; 或（iii）部分（i）和（ii）中任一项的肽或肽衍生物的逆转型变体，其中所述肽或肽衍生物具有促凝活性。 一种肽或肽衍生物，其包含：（i）包含成纤维细胞的氨基酸序列; 或（ii）在成纤维细胞中包含一个，两个，三个，四个，五个或六个氨基酸取代的变体氨基酸序列，其中所述肽或肽衍生物具有促凝活性。
-
公开(公告)号：US10287319B2
公开(公告)日：2019-05-14
申请号：US15443949
申请日：2017-02-27
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Friedrich Scheiflinger , Michael Dockal
IPC: C07K7/06 , C07K14/755 , C07K7/08 , C07K1/04 , A61K38/00
Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.069 seconds)
